Clinic
Prospect Rockville Hospital, INC.
Prospect Rockville Hospital, INC. was paid $30.06M by Medicaid between Jan 2018 and Dec 2024, across 228 billing codes. Its largest line is G0384, Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) — 21% of everything it billed.
33Billing provider infoPROSPECT ROCKVILLE HOSPITAL, INC.
VERNON, CT 06066
VERNON, CT 06066
33aNPI1205283538assigned 05/17/2016
33bProvider typeEmergency Care Clinic/Center
28Total paid$30.06M
24GClaims771,392
24DCodes billed228
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Care Clinic/Center providers in Connecticut
Rank by total paid#6 of 6
Median peer was paid$80.66M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ELDERS, ROBERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 119,694 | $4.28M | |
| 2019 | 117,561 | $4.70M | |
| 2020 | 94,434 | $3.45M | |
| 2021 | 115,256 | $4.31M | |
| 2022 | 123,670 | $4.96M | |
| 2023 | 104,229 | $4.26M | |
| 2024incomplete | 96,548 | $4.10M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 21% | 10,368 | 8,970 | $6.35M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 9,728 | 8,406 | $3.34M |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 6.9% | 9,196 | 8,177 | $2.07M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.4% | 7,983 | 6,987 | $1.94M |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 6.3% | 10,679 | 9,688 | $1.88M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.0% | 11,747 | 10,018 | $1.81M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.5% | 9,386 | 8,239 | $1.65M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.9% | 12,265 | 9,279 | $1.17M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 4,325 | 3,992 | $1.03M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.3% | 23,236 | 7,055 | $699K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.9% | 14,820 | 4,923 | $570K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.8% | 4,707 | 4,623 | $545K |
216 more codes
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.8% | 873 | $534K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 9,023 | $486K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 4,749 | $476K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 7,906 | $439K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 10,587 | $414K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 7,972 | $412K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 2,608 | $357K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,011 | $272K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,785 | $262K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,121 | $255K |
| 97010 | <1% | 12,702 | $189K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,052 | $177K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,700 | $170K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,518 | $170K |
| 77065 | Tomosynthesis, mammo | <1% | 1,217 | $122K |
| 97161 | <1% | 1,983 | $120K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 269 | $117K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,140 | $116K |
| 76642 | <1% | 1,712 | $95K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 985 | $94K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,474 | $92K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,023 | $88K |
| 76641 | <1% | 1,464 | $84K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,729 | $81K |
| 97162 | <1% | 1,327 | $73K | |
| 93971 | <1% | 940 | $63K | |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 932 | $62K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,450 | $62K |
| 97014 | <1% | 4,011 | $61K | |
| 97035 | <1% | 3,740 | $61K | |
| 76830 | Ultrasound, transvaginal | <1% | 680 | $58K |
| 82947 | <1% | 23,194 | $57K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 506 | $55K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 68 | $51K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 953 | $47K |
| 71250 | <1% | 878 | $47K | |
| 73564 | <1% | 1,743 | $44K | |
| 73610 | <1% | 1,939 | $43K | |
| 72100 | <1% | 1,483 | $41K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 457 | $39K |
| 73030 | <1% | 1,995 | $35K | |
| 73630 | <1% | 2,012 | $29K | |
| 97012 | <1% | 507 | $28K | |
| 73130 | <1% | 1,632 | $28K | |
| 77080 | <1% | 289 | $27K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 114 | $24K |
| 73110 | <1% | 1,087 | $23K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,472 | $23K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,279 | $23K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 322 | $21K |
| 97113 | <1% | 382 | $19K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 448 | $15K |
| G0378 | Hospital observation service, per hour | <1% | 3,343 | $15K |
| 77066 | Tomosynthesis, mammo | <1% | 137 | $14K |
| 73502 | <1% | 1,059 | $14K | |
| 0012A | <1% | 362 | $13K | |
| 0011A | <1% | 425 | $13K | |
| 76536 | <1% | 150 | $11K | |
| 73562 | <1% | 977 | $10K | |
| 73140 | <1% | 389 | $10K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 849 | $9K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 849 | $9K |
| 70486 | <1% | 154 | $7K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 25 | $7K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 40 | $6K |
| 72110 | <1% | 97 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 42,077 | $6K |
| 97165 | <1% | 85 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 63 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,825 | $5K |
| 76801 | <1% | 41 | $4K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,893 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,097 | $4K |
| 74018 | <1% | 157 | $4K | |
| 80051 | <1% | 23,769 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,201 | $3K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 55 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,464 | $3K |
| 97032 | <1% | 100 | $2K | |
| 80053 | Comprehensive metabolic panel | <1% | 737 | $2K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,146 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,516 | $2K |
| 93970 | <1% | 12 | $2K | |
| 82565 | <1% | 23,917 | $2K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 13 | $2K |
| 72072 | <1% | 39 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 19 | $2K |
| 85610 | <1% | 3,780 | $2K | |
| J3490 | Unclassified drugs | <1% | 35,612 | $1K |
| 80061 | Lipid panel | <1% | 123 | $1K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,664 | $1K |
| 73080 | <1% | 57 | $960.90 | |
| 81025 | <1% | 8,821 | $892.97 | |
| 72040 | <1% | 40 | $870.12 | |
| 96367 | <1% | 14 | $786.65 | |
| 83735 | <1% | 6,735 | $750.39 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 71 | $706.05 |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 164 | $622.51 |
| 84520 | <1% | 23,812 | $592.35 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 462 | $575.75 |
| 0002A | <1% | 54 | $538.97 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,142 | $538.57 |
| 85027 | <1% | 1,972 | $524.16 | |
| 83880 | <1% | 2,670 | $513.56 | |
| 84484 | <1% | 7,926 | $494.77 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,325 | $456.76 |
| 71101 | <1% | 24 | $395.43 | |
| 87070 | <1% | 2,388 | $382.54 | |
| 77061 | <1% | 133 | $360.80 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,870 | $336.84 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 15 | $332.97 |
| 93017 | <1% | 12 | $331.74 | |
| 82553 | <1% | 544 | $295.97 | |
| 83690 | <1% | 9,525 | $295.87 | |
| 81001 | <1% | 7,847 | $257.39 | |
| 82247 | <1% | 17,951 | $256.81 | |
| 0001A | <1% | 45 | $252.99 | |
| 87186 | <1% | 1,573 | $242.31 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 97 | $240.11 |
| 85007 | <1% | 1,489 | $221.82 | |
| 82040 | <1% | 17,980 | $214.23 | |
| 84450 | <1% | 18,075 | $212.28 | |
| 81002 | <1% | 12,273 | $212.08 | |
| 84075 | <1% | 17,948 | $204.02 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 198 | $198.50 |
| 85379 | <1% | 2,341 | $190.68 | |
| 73090 | <1% | 12 | $182.18 | |
| 84460 | <1% | 18,083 | $182.10 | |
| 73590 | <1% | 14 | $181.06 | |
| 84155 | <1% | 17,961 | $152.87 | |
| 86900 | <1% | 936 | $146.65 | |
| 94761 | <1% | 2,451 | $144.05 | |
| 86885 | <1% | 61 | $137.31 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,002 | $133.42 |
| 83605 | <1% | 2,764 | $111.37 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 26 | $110.00 |
| 84702 | <1% | 561 | $106.65 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,565 | $105.17 |
| 85730 | <1% | 573 | $105.03 | |
| 90714 | <1% | 594 | $101.99 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 65 | $101.12 |
| 82728 | <1% | 158 | $94.34 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,458 | $90.09 |
| 86140 | <1% | 397 | $87.64 | |
| 96376 | <1% | 2,769 | $84.59 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 203 | $83.23 |
| 82310 | <1% | 3,091 | $79.03 | |
| 82948 | <1% | 2,873 | $75.03 | |
| 87040 | <1% | 1,634 | $74.35 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 882 | $71.30 |
| 87077 | <1% | 393 | $66.22 | |
| 84145 | <1% | 507 | $61.82 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 733 | $55.57 |
| 87205 | <1% | 367 | $52.91 | |
| 84100 | <1% | 793 | $50.60 | |
| 85652 | <1% | 141 | $49.79 | |
| 86901 | <1% | 936 | $47.49 | |
| 82550 | <1% | 261 | $37.56 | |
| 91300 | <1% | 82 | $33.33 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,567 | $31.58 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,447 | $28.18 |
| 87420 | <1% | 525 | $24.54 | |
| 36416 | <1% | 2,878 | $20.11 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 908 | $19.69 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,421 | $18.72 |
| 86618 | <1% | 82 | $16.27 | |
| 82140 | <1% | 28 | $13.92 | |
| 80164 | <1% | 13 | $12.94 | |
| 80076 | <1% | 25 | $12.91 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 273 | $10.54 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,168 | $9.74 |
| 86403 | <1% | 116 | $9.73 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,233 | $9.32 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,318 | $5.12 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 618 | $4.05 |
| 94760 | <1% | 914 | $3.51 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 346 | $3.22 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,535 | $3.19 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,477 | $3.13 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 993 | $3.08 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,100 | $1.84 |
| A9150 | Non-prescription drugs | <1% | 1,232 | $1.66 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 285 | $1.31 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 210 | $1.10 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 30 | $0.11 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 189 | $0.00 |
| 88313 | 0% | 284 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 543 | $0.00 |
| 82075 | 0% | 274 | $0.00 | |
| 82800 | 0% | 14 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 85 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 143 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 117 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 42 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 123 | $0.00 |
| 77062 | 0% | 26 | $0.00 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 36 | $0.00 |
| 93041 | 0% | 134 | $0.00 | |
| 88342 | 0% | 327 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 341 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 123 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 2,466 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,545 | $0.00 |
| A9270 | Non-covered item or service | 0% | 178 | $0.00 |
| 83615 | 0% | 95 | $0.00 | |
| 84703 | 0% | 100 | $0.00 | |
| 12001 | 0% | 66 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 38 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 48 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 252 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 97 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 57 | $0.00 |
| 91301 | 0% | 782 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 13 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 13 | $0.00 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialELDERS, ROBERT (SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Prospect Waterbury, INC. | Waterbury, CT | $84.62M |
| Prospect Manchester Hospital, INC. | Manchester, CT | $69.20M |
| Prospect Chartercare RWMC, LLC | Providence, RI | $57.10M |
| Prospect CCMC, LLC | Chester, PA | $40.89M |
| Prospect CT Medical Foundation, INC. | Manchester, CT | $34.07M |
| Prospect Chartercare Sjhsri, LLC | North Providence, RI | $10.94M |
| Prospect DCMH, LLC | Drexel Hill, PA | $10.37M |
| Prospect CCMC, LLC | Chester, PA | $5.46M |
| Alta Los Angeles Hospitals, INC. | Los Angeles, CA | $5.42M |
| Prospect CCMC, LLC | Chester, PA | $5.03M |
| Prospect CCMC, LLC | Chester, PA | $3.71M |
| Prospect Chartercare Physicians, LLC | Cranston, RI | $2.31M |
| Prospect Echn Home Health, INC. | Vernon, CT | $1.75M |
| Prospect Waterbury Home Health, INC. | Watertown, CT | $1.30M |
| Prospect Health Access Network, INC. | Chester, PA | $1.22M |
| Alta Newport Hospital, LLC | Tustin, CA | $1.16M |
| Prospect Health Access Network, INC. | Crum Lynne, PA | $924K |
| Prospect Health Access Network, INC. | Chester, PA | $872K |
| Prospect Chartercare Sjhsri, LLC | North Providence, RI | $858K |
| Prospect Health Access Network, INC. | Drexel Hill, PA | $815K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.